HIV-1 remodels the spatial organization of its co-receptor, CXCR4, on T cell membranes, showing that viral entry requires receptor clustering rather than simple receptor binding.

While HIV-1 and HIV-2 closely relate and can cause similar health concerns, there are some important differences to know — especially when it comes to transmission, testing, and treatment. HIV-1 and ...

Researchers mapped more than 100 mutations that allow diverse HIV-1 strains to evade broadly neutralizing antibodies.

Broadly neutralizing antibodies (bNAbs) are among the most promising new treatments for HIV, offering the potential to forego traditional daily dose of antiretroviral drugs.

Researchers from Queen Mary University of London have uncovered a previously unknown mechanism by which HIV-1 can infect ...

Among some patients with human immunodeficiency virus type 1 (HIV-1) infection who have undergone multiple antiretroviral therapies and have limited options for treatment, new classes of ...

What Is Idvynso, and Why Does It Matter? Idvynso (doravirine/islatravir) is a fixed-dose combination of two prescription medicines and is taken as a single, once ...

Idvynso is a new once-daily, two-drug oral regimen for adults with HIV-1 who are virologically suppressed and have no history of treatment failure.

At week 48, an HIV-1 RNA level of 50 copies per milliliter or higher was found in 6 of 283 participants (2.1%) who received long-acting therapy and in 7 of 283 (2.5%) who received oral therapy ...

Researchers from Queen Mary University of London have uncovered a previously unknown mechanism by which HIV-1 can infect ...